Healthcare Industry News: GE Healthcare
News Release - January 21, 2008
Candela Names Lewis J. Levine Vice President of EngineeringWAYLAND, Mass.--(HSMN NewsFeed)--Candela Corporation (NASDAQ: CLZR ) announced today that Lewis Levine has joined the company as Vice President of Engineering. Mr. Levine will oversee all engineering resources and drive technical initiatives related to new product development.
“Lew brings over 15 years of engineering and new product development experience within the medical device industry to Candela. The addition of new leadership to our engineering division will further our ability to effectively deliver innovative laser solutions to the dynamic aesthetic industry,” said Jay Caplan, Chief Operating Officer.
Most recently, Mr. Levine served as Vice President of Research and Development at Datascope Corporation, a Montvale, New Jersey-based medical device company, where he led efforts to improve product development methods within the Patient Monitoring Division. Prior to this role, he directed the development of a unique technology platform for a medical device start-up which was later acquired by GE Healthcare. Additionally, he is named on eight issued and pending patents.
Mr. Levine earned a Bachelor’s degree from Rensselaer Polytechnic Institute and a Master of Business Administration degree from Northeastern University.
About CANDELA: Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 18 years ago, and currently has an installed base of an estimated 12,000 lasers worldwide. Visit Candela on the Web at http://www.candelalaser.com.
Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, the risk of an adverse judgment in the patent litigation with Palomar Medical Technologies, Inc., dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.